FDA-Approved Devices for Home Movement Rehabilitation After Stroke: Availability, User Needs, Information Gaps, and Accompanying Dataset

Technologies for home movement rehabilitation after stroke are rapidly expanding. However, for consumers, the number and nature of available products are unclear, and the information provided by device manufacturers varies widely. To understand this landscape, we used the U.S. Food and Drug Administration (FDA) database to identify devices for stroke rehabilitation suitable for home use. We then surveyed 13 individuals with stroke to determine what information they most wanted about home-based reha-bilitation devices and contacted manufacturers to obtain those details. Thirteen FDA codes were associated with stroke rehabilitation devices, encompassing 58 devices produced by 41 companies. Nearly half were categorized under two codes: QKC (in-teractive rehabilitation exercise devices) and GZI (neuromuscular stimulators). Among devices for which information was available, 71% received FDA clearance after 2015, and 23% cost under $1,000. The top information priorities for individuals with stroke were required usage to achieve therapeutic benefit, expected benefit, ease of use, and motivational features. Despite repeated outreach, only 44% of companies responded to our queries; among those that did, details were vague and variable. These results con-firm that a large and growing number of FDA-approved devices are now available for home-based post-stroke motor rehabilitation. We further identify a need to establish industry standards for reporting ease of use, motivational effectiveness, and dose–response characteristics to help the intended consumers select appropriate technolo-gies. We include the dataset for future reference.